Erratum: An HIV cure: Feasibility, discovery, and implementation (Journal of the American Medical Association (2014) 312, 4 (335-336) DOI:10.1001/jama.2014.4754);An HIV cure: Feasibility, discovery, and implementation

JAMA

Volumn 312, Issue 4, 2014, Pages 335-336

  Fauci, Anthony S ^a   Marston, Hilary D ^a   Folkers, Gregory K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; CLINICAL EFFECTIVENESS; EARLY INTERVENTION; FEASIBILITY STUDY; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIFE EXPECTANCY; LONG TERM CARE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REBOUND; REMISSION; SHORT SURVEY; VIRAL CLEARANCE; VIRUS INHIBITION;

ANTI-RETROVIRAL AGENTS; ENDPOINT DETERMINATION; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; REMISSION INDUCTION; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 84904545962     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.9686     Document Type: Erratum

References (9)

1. UN Joint Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. UNAIDS website. http://www.unaids.org/en/media/ unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report- 2013-en.pdf. Accessed July 10, 2014.
2. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-698.
3. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901-910.
4. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20(4):425-429.
5. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828-1835.
6. National Institute of Allergy and Infectious Diseases (NIAID). "Mississippi Baby" Now Has Detectable HIV, Researchers Find. NIAID website. http://www.niaid.nih.gov/news/newsreleases/2014/Pages/ MississippiBabyHIV.aspx. July 10, 2014. Accessed July 10, 2014.
7. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.
8. West AP Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014;156(4):633-648.
9. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. 2014;20(3):296-300.